shutterstock_1595586766_ken_wolter

Ken Wolter / Shutterstock.com

9 November 2020AmericasSarah Morgan

EPO reveals decision behind Broad patent revocation

The European Patent Office (EPO) has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More on this story

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More on this story

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?